European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes

View source ↗

Summary

EMA is investigating pancreatic risk findings associated with GLP-1–based therapies used for type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus